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Erratum
Focus on kidney cancer
In this Focus (Cancer Cell 6, pp. 223–228), the legends for Figures 1 and 2 were reversed. They
are reprinted below with the proper captions. Additionally, Figure 1 should be cited at the end
of the second-to-last sentence of the section “Studies of dominantly inherited, epithelial forms
of renal carcinoma,” the citation at the end of the last paragraph of the section “VHL gene pathway:
Opportunity for disease-specific approaches to therapy” should refer to Figure 2, not Figure 1,
and the citation to Figure 2 at the end of the first paragraph of the section “Sporadic kidney
cancer” should be disregarded.
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Figure 1. Kidney cancer is not a single disease, it is made up of
a number of different types of cancer that occur in the kidney
These different types of kidney cancer are characterized by dif-
ferent histologies, have different clinical courses, respond differ-
ently to therapy, and are associated with alteration of different
genes. Modified from Linehan et al. (2003).

Figure 2. Molecular targeting of the VHL pathway in clear cell
renal carcinoma
Mutation of the VHL gene in clear cell kidney cancer results
in increased accumulation of HIF and the resulting increase in
transcription of downstream targets such as VEGFR, EGFR, and
TGF (A). Mutation of the VHL gene in the  domain (shown here)
inhibits binding to elongin C and formation of the VHL complex
(Stebbins et al., 1999). Mutation in other parts of the gene, such
as the  domain, prevents binding to and ubiquitin mediated
degradation of HIF (Ohh et al., 2000). Potential disease-specific
therapeutic approaches include agents which block the func-
tion of HIF (B), VEGFR, or EGFR (C). Modified from Linehan et al.
(2002, 2003).
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